Chemoinformaics analysis of (+)-epi-beta-santalol
| Molecular Weight | 262.393 | nRot | 5 |
| Heavy Atom Molecular Weight | 236.185 | nRig | 11 |
| Exact Molecular Weight | 262.193 | nRing | 2 |
| Solubility: LogS | -5.06 | nHRing | 0 |
| Solubility: LogP | 4.247 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 45 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 17 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 47.3306 |
| nHD | 0 | BPOL | 28.6874 |
| QED | 0.546 |
| Synth | 4.744 |
| Natural Product Likeliness | 3.015 |
| NR-PPAR-gamma | 0.009 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.009 |
| Pgp-sub | 0 |
| HIA | 0.005 |
| CACO-2 | -4.534 |
| MDCK | 0.0000214 |
| BBB | 0.905 |
| PPB | 0.834718 |
| VDSS | 1.991 |
| FU | 0.175181 |
| CYP1A2-inh | 0.396 |
| CYP1A2-sub | 0.17 |
| CYP2c19-inh | 0.259 |
| CYP2c19-sub | 0.84 |
| CYP2c9-inh | 0.166 |
| CYP2c9-sub | 0.343 |
| CYP2d6-inh | 0.019 |
| CYP2d6-sub | 0.473 |
| CYP3a4-inh | 0.449 |
| CYP3a4-sub | 0.302 |
| CL | 9.541 |
| T12 | 0.091 |
| hERG | 0.009 |
| Ames | 0.012 |
| ROA | 0.021 |
| SkinSen | 0.406 |
| Carcinogencity | 0.729 |
| EI | 0.688 |
| Respiratory | 0.636 |
| NR-Aromatase | 0.21 |
| Antiviral | Yes |
| Prediction | 0.783635 |